The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Skp2 is oncogenic and overexpressed in human cancers
Open accessAbstract
Skp2 is a member of the F-box family of substrate-recognition subunits of SCF ubiquitin–protein ligase complexes that has been implicated in the ubiquitin-mediated degradation of several key regulators of mammalian G 1 progression, including the cyclin-dependent kinase inhibitor p27, a dosage-dependent tumor suppressor protein. In this study, we examined Skp2 and p27 protein expression by immunohistochemistry in normal oral epithelium and in different stages of malignant oral cancer progression, including dysplasia and oral squamous cell carcinoma. We found that increased levels of Skp2 protein are associated with reduced p27 in a subset of oral epithelial dysplasias and carcinomas compared with normal epithelial controls. Tumors with high Skp2 (>20% positive cells) expression invariably showed reduced or absent p27 and tumors with high p27 (>20% positive cells) expression rarely showed Skp2 positivity. Increased Skp2 protein levels were not always correlated with increased cell proliferation (assayed by Ki-67 staining), suggesting that alterations of Skp2 may contribute to the malignant phenotype without affecting proliferation. Skp2 protein overexpression may lead to accelerated p27 proteolysis and contribute to malignant progression from dysplasia to oral epithelial carcinoma. Moreover, we also demonstrate that Skp2 has oncogenic potential by showing that Skp2 cooperates with H-Ras G12V to malignantly transform primary rodent fibroblasts as scored by colony formation in soft agar and tumor formation in nude mice. The observations that Skp2 can mediate transformation and is up-regulated during oral epithelial carcinogenesis support a role for Skp2 as a protooncogene in human tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27
Carrano, A. C., Eytan, E., Hershko, A., & Pagano, M. (1999) · Nature Cell Biology · doi:10.1038/12013 · Cited by 1,543
SCF and Cullin/RING H2-Based Ubiquitin Ligases
Deshaies, R. J. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.435 · Cited by 1,242
Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentinc, M., Draetta, G. F., Jessup, J. M., & Pagano, M. (1997) · Nature Medicine · doi:10.1038/nm0297-231 · Cited by 1,031
Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R., & Roberts, J. M. (1997) · Nature Medicine · doi:10.1038/nm0297-222 · Cited by 901
Catzavelos, C., Bhattacharya, N., Ung, Y. C., Wilson, J. A., Roncari, L., Sandhu, C., Shaw, P., Yeger, H., Morava-Protzner, I., Kapusta, L., et al. (1997) · Nature Medicine · doi:10.1038/nm0297-227 · Cited by 823
Self-citationTsvetkov, L. M., Yeh, K.-H., Lee, S.-J., Sun, H., & Zhang, H. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80290-5 · Cited by 791
The murine gene p27Kip1 is haplo-insufficient for tumour suppression
Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M., & Kemp, C. J. (1998) · Nature · doi:10.1038/24179 · Cited by 784
Nakayama, K. (2000) · The EMBO Journal · doi:10.1093/emboj/19.9.2069 · Cited by 717
p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells
Sutterlüty, H., Chatelain, E., Marti, A., Wirbelauer, C., Senften, M., Müller, U., & Krek, W. (1999) · Nature Cell Biology · doi:10.1038/12027 · Cited by 700
Self-citation
Cited by
The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction
Glickman, M. H., & Ciechanover, A. (2002) · Physiological Reviews · doi:10.1152/physrev.00027.2001 · Cited by 4,237
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
Structure of the Cul1–Rbx1–Skp1–F boxSkp2 SCF ubiquitin ligase complex
Zheng, N., Schulman, B. A., Song, L., Miller, J. J., Jeffrey, P. D., Wang, P., Chu, C., Koepp, D. M., Elledge, S. J., Pagano, M., et al. (2002) · Nature · doi:10.1038/416703a · Cited by 1,507
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
Ubiquitin ligases: cell-cycle control and cancer
Nakayama, K. I., & Nakayama, K. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1881 · Cited by 1,433
The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy
Chu, I. M., Hengst, L., & Slingerland, J. M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2347 · Cited by 990
Self-citationWelcker, M., Orian, A., Jin, J., Grim, J. A., Harper, J. W., Eisenman, R. N., & Clurman, B. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402770101 · Cited by 941
Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer
Frescas, D., & Pagano, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2396 · Cited by 890
Phosphorylation‐dependent degradation of c‐Myc is mediated by the F‐box protein Fbw7
Yada, M., Hatakeyama, S., Kamura, T., Nishiyama, M., Tsunematsu, R., Imaki, H., Ishida, N., Okumura, F., Nakayama, K., & Nakayama, K. I. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600217 · Cited by 808
Drug discovery in the ubiquitin–proteasome system
Nalepa, G., Rolfe, M., & Harper, J. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2056 · Cited by 608
The Ubiquitin-Proteasome Pathway and Its Role in Cancer
Mani, A., & Gelmann, E. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.081 · Cited by 549
Roles of F-box proteins in cancer
Wang, Z., Liu, P., Inuzuka, H., & Wei, W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3700 · Cited by 523
Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex
Wei, W., Ayad, N. G., Wan, Y., Zhang, G.-J., Kirschner, M. W., & Kaelin, W. G. (2004) · Nature · doi:10.1038/nature02381 · Cited by 493
Farrell, A. S., & Sears, R. C. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014365 · Cited by 468
A hitchhiker's guide to the cullin ubiquitin ligases: SCF and its kin
Willems, A. R., Schwab, M., & Tyers, M. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2004.09.027 · Cited by 464
MYC Deregulation in Primary Human Cancers
Kalkat, M., De Melo, J., Hickman, K., Lourenco, C., Redel, C., Resetca, D., Tamachi, A., Tu, W., & Penn, L. (2017) · Genes · doi:10.3390/genes8060151 · Cited by 443
Skp2 Regulates Myc Protein Stability and Activity
Kim, S. Y., Herbst, A., Tworkowski, K. A., Salghetti, S. E., & Tansey, W. P. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00173-4 · Cited by 440
Drugging the undruggables: exploring the ubiquitin system for drug development
Huang, X., & Dixit, V. M. (2016) · Cell Research · doi:10.1038/cr.2016.31 · Cited by 427
Lipkowitz, S., & Weissman, A. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3120 · Cited by 415
von der Lehr, N., Johansson, S., Wu, S., Bahram, F., Castell, A., Cetinkaya, C., Hydbring, P., Weidung, I., Nakayama, K., Nakayama, K. I., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00193-x · Cited by 408
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence
Lin, H.-K., Chen, Z., Wang, G., Nardella, C., Lee, S.-W., Chan, C.-H., Yang, W.-L., Wang, J., Egia, A., Nakayama, K. I., et al. (2010) · Nature · doi:10.1038/nature08815 · Cited by 400
Deregulated degradation of the cdk inhibitor p27 and malignant transformation
Bloom, J., & Pagano, M. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00098-6 · Cited by 374
Regulation of the cell cycle by SCF-type ubiquitin ligases
NAKAYAMA, K., & NAKAYAMA, K. (2005) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2005.02.010 · Cited by 360
Ubiquitin signaling in cell cycle control and tumorigenesis
Dang, F., Nie, L., & Wei, W. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00648-0 · Cited by 348
Méndez, J., Zou-Yang, X. H., Kim, S.-Y., Hidaka, M., Tansey, W. P., & Stillman, B. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00467-7 · Cited by 320
Structural Basis of the Cks1-Dependent Recognition of p27Kip1 by the SCFSkp2 Ubiquitin Ligase
Hao, B., Zheng, N., Schulman, B. A., Wu, G., Miller, J. J., Pagano, M., & Pavletich, N. P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.09.003 · Cited by 301
Fu, X., Richards, D. E., Fleck, B., Xie, D., Burton, N., & Harberd, N. P. (2004) · The Plant Cell · doi:10.1105/tpc.021386 · Cited by 295
Nakada, C., Matsuura, K., Tsukamoto, Y., Tanigawa, M., Yoshimoto, T., Narimatsu, T., Nguyen, L., Hijiya, N., Uchida, T., Sato, F., et al. (2008) · The Journal of Pathology · doi:10.1002/path.2437 · Cited by 269
The pleiotropic actions of vitamin D
Lin, R., & White, J. H. (2004) · BioEssays · doi:10.1002/bies.10368 · Cited by 267
Gao, D., Inuzuka, H., Tseng, A., Chin, R. Y., Toker, A., & Wei, W. (2009) · Nature Cell Biology · doi:10.1038/ncb1847 · Cited by 267
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer
Signoretti, S., Marcotullio, L. D., Richardson, A. L., Ramaswamy, S., Isaac, B. M., Rué, M., Monti, F., Loda, M. F., & Pagano, M. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15795 · Cited by 257
RetractedJi, P., Jiang, H., Rekhtman, K., Bloom, J., Ichetovkin, M., Pagano, M., & Zhu, L. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.09.029 · Cited by 170
Li, G. Z., Okada, T., Kim, Y.-M., Agaram, N. P., Sanchez-Vega, F., Shen, Y., Tsubokawa, N., Rios, J., Martin, A. S., Dickson, M. A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1269 · Cited by 42
Metadata
- Authors
- Gstaiger, M., Jordan, R., Lim, M., Catzavelos, C., Mestan, J., Slingerland, J., & Krek, W.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2001-04-17
- Volume
- 98
- Issue
- 9
- Pages
- 5043-5048
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2056234356
- Cited by
- 505
- References
- 25
- FWCI
- 11.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.